Overview / Abstract: |
This activity will address the current treatment landscape as it compares to clinical trials in development focusing on FcRn modulation as a therapeutic target for myasthenia gravis (MG). We will review FcRn inhibitor therapeutic agents and discuss how these therapies may effectively change the management of patients with MG. |
Expiration |
Jun 16, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1 AMA/PRA Cat 1 Credit |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Gil I. Wolfe, MD, FAAN |
Sponsors / Supporters / Grant Providers |
argenx Pharmaceuticals |
Keywords / Search Terms |
EXCEL Continuing Education myasthenia gravis, generalized myasthenia gravis, neurology, ophthalmology, neuromuscular, FcRn inhibition, IgG anitbodies. Free CE CME |